Tasca Therapeutics Expanded Access Policy

Patients with serious or immediately life-threatening diseases who are not eligible for, or cannot participate in, a clinical trial—and who have no comparable or satisfactory alternative treatment options—may consider expanded access programs, also known as “compassionate use”. Expanded access is a potential pathway for patients to gain access to an investigational medical product outside of clinical trials. More information about expanded access is available from the U.S. Food and Drug Administration at Expanded Access.

Tasca Therapeutics (Tasca) recognizes the importance of expanded access programs. At this time, however, access to Tasca’s investigational medicines is available only through participation in clinical trials. Tasca believes that studying unapproved therapies in controlled clinical trials is a critical step in generating the safety and efficacy data needed to support health authority review and, ultimately, make these therapies available to more patients. Tasca is committed to reevaluate this policy as sufficient safety and efficacy data become available from controlled clinical trials.
For more information on Tasca Therapeutics sponsored clinical trials, search “Tasca” at clinicaltrials.gov